In view of improving pathological detection of the tumor and comprehensive molecular and genomic profiling, sporadic case studies and small trials have demonstrated disease response to targeted drugs such as Bcl-2 inhibitors, sunitinib, pazopanib, imatinib, nivolumab, pembrolizumab, vismodegib, everolimus, cobimetinib, trametinib, palbociclib, azacytidine, and decitabine [12]. The gene discussed is BCL2; the disease is neoplasm.